Works about BRUTON tyrosine kinase
Results: 768
Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL).
- Published in:
- Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-025-04753-0
- By:
- Publication type:
- Article
Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: a single-center retrospective analysis of 118 cases.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 389, doi. 10.1007/s00277-024-06147-3
- By:
- Publication type:
- Article
Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 701, doi. 10.1007/s00277-024-05978-4
- By:
- Publication type:
- Article
Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies.
- Published in:
- BMC Pharmacology & Toxicology, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s40360-024-00832-9
- By:
- Publication type:
- Article
A Structure‐Activity Investigation of the Fungal Metabolite (−)‐TAN‐2483B: Inhibition of Bruton's Tyrosine Kinase.
- Published in:
- Chemistry - A European Journal, 2024, v. 30, n. 35, p. 1, doi. 10.1002/chem.202401051
- By:
- Publication type:
- Article
Scaffold‐Oriented Asymmetric Catalysis: Conformational Modulation of Transition State Multivalency during a Catalyst‐Controlled Assembly of a Pharmaceutically Relevant Atropisomer.
- Published in:
- Chemistry - A European Journal, 2024, v. 30, n. 30, p. 1, doi. 10.1002/chem.202401109
- By:
- Publication type:
- Article
Synthetic Reprogramming of Kinases Expands Cellular Activities of Proteins.
- Published in:
- Angewandte Chemie, 2022, v. 134, n. 29, p. 1, doi. 10.1002/ange.202202770
- By:
- Publication type:
- Article
Bioactivation and reactivity research advances – 2021 year in review.
- Published in:
- Drug Metabolism Reviews, 2022, v. 54, n. 3, p. 246, doi. 10.1080/03602532.2022.2097254
- By:
- Publication type:
- Article
Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway.
- Published in:
- PeerJ, 2021, p. 1, doi. 10.7717/peerj.12571
- By:
- Publication type:
- Article
Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2022, v. 37, n. 1, p. 226, doi. 10.1080/14756366.2021.1999237
- By:
- Publication type:
- Article
Discovery of new symmetrical and asymmetrical nitrile-containing 1,4-dihydropyridine derivatives as dual kinases and P-glycoprotein inhibitors: synthesis, in vitro assays, and in silico studies.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2022, v. 37, n. 1, p. 2489, doi. 10.1080/14756366.2022.2120478
- By:
- Publication type:
- Article
Drug screening approaches for small-molecule compounds in cancer-targeted therapy.
- Published in:
- Journal of Drug Targeting, 2025, v. 33, n. 3, p. 368, doi. 10.1080/1061186X.2024.2427185
- By:
- Publication type:
- Article
Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma—a single-center retrospective study.
- Published in:
- Neurological Sciences, 2024, v. 45, n. 6, p. 2931, doi. 10.1007/s10072-024-07348-4
- By:
- Publication type:
- Article
Preserving the brain: forum on neurodegenerative diseases.
- Published in:
- Neurological Sciences, 2023, v. 44, n. 7, p. 2613, doi. 10.1007/s10072-023-06721-z
- By:
- Publication type:
- Article
Bruton's tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01214-y
- By:
- Publication type:
- Article
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton's tyrosine kinase expression levels.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01196-3
- By:
- Publication type:
- Article
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01044-4
- By:
- Publication type:
- Article
Update on the management of relapsed/refractory chronic lymphocytic leukemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01001-1
- By:
- Publication type:
- Article
Update on the management of relapsed/refractory chronic lymphocytic leukemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01001-1
- By:
- Publication type:
- Article
Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00927-2
- By:
- Publication type:
- Article
Zanubrutinib: past, present, and future.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00902-x
- By:
- Publication type:
- Article
Zanubrutinib: past, present, and future.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00902-x
- By:
- Publication type:
- Article
Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00916-5
- By:
- Publication type:
- Article
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00890-y
- By:
- Publication type:
- Article
DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00781-8
- By:
- Publication type:
- Article
Chronic lymphocytic leukemia treatment algorithm 2022.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00756-9
- By:
- Publication type:
- Article
Determining drug dose in the era of targeted therapies: playing it (un)safe?
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 8, p. 1, doi. 10.1038/s41408-022-00720-7
- By:
- Publication type:
- Article
Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 5, p. 1, doi. 10.1038/s41408-022-00675-9
- By:
- Publication type:
- Article
A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-72121-8
- By:
- Publication type:
- Article
Investigating the molecular mechanisms underlying the co-occurrence of Parkinson's disease and inflammatory bowel disease through the integration of multiple datasets.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-67890-1
- By:
- Publication type:
- Article
Regulation of Cx43 Gap Junction Intercellular Communication by Bruton's Tyrosine Kinase and Interleukin-2-Inducible T-Cell Kinase.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 4, p. 660, doi. 10.3390/biom13040660
- By:
- Publication type:
- Article
Targeting inflammation in traumatic injury: entering a new era.
- Published in:
- Intensive Care Medicine, 2023, v. 49, n. 8, p. 977, doi. 10.1007/s00134-023-07152-2
- By:
- Publication type:
- Article
Eyes on New Product Development.
- Published in:
- Journal of Ocular Pharmacology & Therapeutics, 2024, v. 40, n. 5, p. 259, doi. 10.1089/jop.2024.0054
- By:
- Publication type:
- Article
The Defenders of the Alveolus Succumb in COVID-19 Pneumonia to SARS-CoV-2 and Necroptosis, Pyroptosis, and PANoptosis.
- Published in:
- Journal of Infectious Diseases, 2023, v. 227, n. 11, p. 1245, doi. 10.1093/infdis/jiad056
- By:
- Publication type:
- Article
Recent advances in CD5<sup>+</sup> diffuse large B-cell lymphoma.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 11, p. 4401, doi. 10.1007/s00277-024-05974-8
- By:
- Publication type:
- Article
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 11, p. 4613, doi. 10.1007/s00277-024-05921-7
- By:
- Publication type:
- Article
Clinical characteristics and prognosis of patients with newly diagnosed primary central nervous system lymphoma: a multicentre retrospective analysis.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 11, p. 4649, doi. 10.1007/s00277-024-05797-7
- By:
- Publication type:
- Article
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 10, p. 4183, doi. 10.1007/s00277-024-05823-8
- By:
- Publication type:
- Article
A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS).
- Published in:
- Annals of Hematology, 2024, v. 103, n. 8, p. 2969, doi. 10.1007/s00277-024-05859-w
- By:
- Publication type:
- Article
Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 7, p. 2231, doi. 10.1007/s00277-023-05486-x
- By:
- Publication type:
- Article
Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 6, p. 2003, doi. 10.1007/s00277-024-05648-5
- By:
- Publication type:
- Article
Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 6, p. 1859, doi. 10.1007/s00277-023-05345-9
- By:
- Publication type:
- Article
Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 5, p. 1779, doi. 10.1007/s00277-024-05721-z
- By:
- Publication type:
- Article
Small lymphocytic lymphoma infiltrating gastrointestinal tract and mimicking inflammatory bowel disease, successfully treated with acalabrutinib.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 3, p. 1021, doi. 10.1007/s00277-023-05585-9
- By:
- Publication type:
- Article
Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 11, p. 3083, doi. 10.1007/s00277-023-05314-2
- By:
- Publication type:
- Article
A prediction model for severe hematological toxicity of BTK inhibitors.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 10, p. 2765, doi. 10.1007/s00277-023-05371-7
- By:
- Publication type:
- Article
Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 7, p. 1789, doi. 10.1007/s00277-023-05255-w
- By:
- Publication type:
- Article
COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 4, p. 811, doi. 10.1007/s00277-023-05147-z
- By:
- Publication type:
- Article
Platelet recovery with ibrutinib therapy in patient with treatment-refractory immune thrombocytopenia.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 1, p. 237, doi. 10.1007/s00277-022-05031-2
- By:
- Publication type:
- Article
Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 1, p. 107, doi. 10.1007/s00277-022-05023-2
- By:
- Publication type:
- Article